PD‑L1 expression is associated with advanced non‑small cell lung cancer

Chen,Zhiquan; Mei,Jiandong; Liu,Lunxu; Wang,Guochen; Li,Zuosheng; Hou,Jingpu; Zhang,Qiuyang; You,Zongbing; Zhang,Liu

doi:10.3892/ol.2016.4741

PD‑L1 expression is associated with advanced non‑small cell lung cancer

Authors:
- Zhiquan Chen
- Jiandong Mei
- Lunxu Liu
- Guochen Wang
- Zuosheng Li
- Jingpu Hou
- Qiuyang Zhang
- Zongbing You
- Liu Zhang
View Affiliations

Affiliations: Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China, Department of Structural and Cellular Biology, Tulane University, New Orleans, LA 70112, USA, Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Thoracic Surgery, Affiliated Hospital of North China University of Science and Technology, Tangshan, Hebei 063000, P.R. China
Published online on: June 16, 2016 https://doi.org/10.3892/ol.2016.4741
Pages: 921-927
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the most common cause of cancer-associated mortalities worldwide. Novel immunotherapies have been developed to improve the clinical outcomes of non‑small cell lung cancer (NSCLC). Antibodies against programmed cell death protein 1 (PD‑1) and programmed cell death protein 1 ligand 1 (PD‑L1) have been tested in clinical trials, and anti‑PD‑1 antibody has been approved for the treatment of NSCLC. The aim of the present study was to assess expression of PD‑1, PD‑L1 and programmed cell death protein 1 ligand 2 (PD‑L2) in 48 patients with NSCLC, using immunohistochemical staining. The results found that 35.4% (17/48) of patients were positive for PD‑1 expression, 64.6% (31/48) were positive for PD‑L1 expression and 45.8% (22/48) were positive for PD‑L2 expression. Neither PD‑1 nor PD‑L2 expression was associated with gender, histology, differentiation status, tumor stage or lymph node metastasis. PD‑L1 expression was not associated with gender, histology, differentiation status or lymph node metastasis; however, PD‑L1 expression was significantly increased in stage III NSCLC (85.7% PD‑L1+) compared with stage I/II NSCLC (55.9% PD‑L1+) (P=0.049).

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zhang S and Zou X: Evaluation on the incidence, mortality and tendency of lung cancer in China. Thoracic Cancer. 1:35–40. 2010. View Article : Google Scholar
3	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
4	Ledford H: Cancer treatment: The killer within. Nature. 508:24–26. 2014. View Article : Google Scholar : PubMed/NCBI
5	Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 363:411–422. 2010. View Article : Google Scholar : PubMed/NCBI
6	Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
7	Harvey RD Immunologic and clinical effects of targeting of pd-1 in lung cancer. Clin Pharmacol Ther. 2014.
8	Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al: Safety, activity, and immune correlates of anti-pd-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
9	Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al: Safety and activity of anti-pd-l1 antibody in patients with advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
10	Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, et al: Durable cancer regression off-treatment and effective reinduction therapy with an anti-pd-1 antibody. Clin Cancer Res. 19:462–468. 2013. View Article : Google Scholar : PubMed/NCBI
11	Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al: Safety and tumor responses with lambrolizumab (anti-pd-1) in melanoma. N Engl J Med. 369:134–144. 2013. View Article : Google Scholar : PubMed/NCBI
12	Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 369:122–133. 2013. View Article : Google Scholar : PubMed/NCBI
13	Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al: Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 372:2521–2532. 2015. View Article : Google Scholar : PubMed/NCBI
14	Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al: Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar : PubMed/NCBI
15	Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al: Predictive correlates of response to the anti-pd-l1 antibody mpdl3280a in cancer patients. Nature. 515:563–567. 2014. View Article : Google Scholar : PubMed/NCBI
16	Cha E, Wallin J and Kowanetz M: Pd-l1 inhibition with mpdl3280a for solid tumors. Semin Oncol. 42:484–487. 2015. View Article : Google Scholar : PubMed/NCBI
17	Ishida Y, Agata Y, Shibahara K and Honjo T: Induced expression of pd-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11:3887–3895. 1992.PubMed/NCBI
18	Nishimura H, Minato N, Nakano T and Honjo T: Immunological studies on pd-1 deficient mice: Implication of pd-1 as a negative regulator for b cell responses. Int Immunol. 10:1563–1572. 1998. View Article : Google Scholar : PubMed/NCBI
19	Nishimura H, Nose M, Hiai H, Minato N and Honjo T: Development of lupus-like autoimmune diseases by disruption of the pd-1 gene encoding an itim motif-carrying immunoreceptor. Immunity. 11:141–151. 1999. View Article : Google Scholar : PubMed/NCBI
20	Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al: Engagement of the pd-1 immunoinhibitory receptor by a novel b7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
21	Dong H, Zhu G, Tamada K and Chen L: B7-h1, a third member of the b7 family, co-stimulates t-cell proliferation and interleukin-10 secretion. Nat Med. 5:1365–1369. 1999. View Article : Google Scholar : PubMed/NCBI
22	Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, et al: Pd-l2 is a second ligand for pd-1 and inhibits t cell activation. Nat Immunol. 2:261–268. 2001. View Article : Google Scholar : PubMed/NCBI
23	Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI, Shalabi A, Shin T, Pardoll DM and Tsuchiya H: B7-dc, a new dendritic cell molecule with potent costimulatory properties for t cells. J Exp Med. 193:839–846. 2001. View Article : Google Scholar : PubMed/NCBI
24	Okazaki T and Honjo T: Pd-1 and pd-1 ligands: From discovery to clinical application. Int Immunol. 19:813–824. 2007. View Article : Google Scholar : PubMed/NCBI
25	Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al: Tumor-associated b7-h1 promotes t-cell apoptosis: A potential mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
26	Keir ME, Butte MJ, Freeman GJ and Sharpe AH: Pd-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 26:677–704. 2008. View Article : Google Scholar : PubMed/NCBI
27	Sharpe AH and Freeman GJ: The b7-cd28 superfamily. Nat Rev Immunol. 2:116–126. 2002. View Article : Google Scholar : PubMed/NCBI
28	Travis WD, Brambilla E, Muller-Hermelink HK and Harris CC: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, IARC Press. pp9–11. 2004.
29	Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK and McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 85:200–206. 1993. View Article : Google Scholar : PubMed/NCBI
30	Kim MY, Koh J, Kim S, Go H, Jeon YK and Chung DH: Clinicopathological analysis of pd-l1 and pd-l2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating t cells and the status of oncogenic drivers. Lung Cancer. 88:24–33. 2015. View Article : Google Scholar : PubMed/NCBI
31	Pan ZK, Ye F, Wu X, An HX and Wu JX: Clinicopathological and prognostic significance of programmed cell death ligand1 (pd-l1) expression in patients with non-small cell lung cancer: A meta-analysis. J Thorac Dis. 7:462–470. 2015.PubMed/NCBI